Iterative Scopes Overview
- Founded
- 2017
- Status
- Private
- Employees
- 78
- Latest Deal Type
- Series B
- Latest Deal Amount
- $150M
- Investors
- 23
Iterative Scopes General Information
Description
Developer of artificial intelligence-based medicine for gastroenterology designed to potentially enhance colorectal cancer screenings. The company aims to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and its real-time computer-aided detection and diagnostic tools are powered by computer vision and machine learning technology is pioneering the application of powerful, proprietary artificial intelligence tools to the practice of gastroenterology and drug development, enabling gastroenterologists to detect and classify lesions in real-time, including those that often elude the human eye and provide doctors with access to deep neural networks, improving patient. outcomes.
Contact Information
Website
www.iterativescopes.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Primary Office
- 14 Arrow Street
- 3rd Floor
- Cambridge, MA 02138
- United States
+1 (703) 000-0000
Iterative Scopes Timeline
Iterative Scopes Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC (Series B) | 30-Dec-2021 | $150M | 00000 | 00000 | Completed | Generating Revenue |
| 4. Early Stage VC (Series A) | 23-Jul-2021 | 0000 | 0000 | 00000 | Completed | Generating Revenue |
| 3. Early Stage VC (Series A) | 17-Feb-2021 | 0000 | 0000 | 0000 | Completed | Generating Revenue |
| 2. Debt - PPP | 29-Apr-2020 | Completed | Generating Revenue | |||
| 1. Grant | 15-May-2018 | $10K | Completed | Startup |
Iterative Scopes Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 0,000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
| Series A-2 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.00 |
| Series A-1 | 7,435,936 | $0.000100 | 8% | $4.03 | $4.03 | 1x | $4.03 | 17.68% |
| Pre-Series A | 9,705,116 | $0.000100 | 8% | $1.36 | $1.36 | 1x | $1.36 | 23.07% |
Iterative Scopes Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of artificial intelligence-based medicine for gastroenterology designed to potentially enhance colorectal canc
Other Healthcare Technology Systems
Cambridge, MA
78
As of 2022
00000
0000
0000-00-00
00000000000
00000
000000 0
a aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea c
00000 0000000000 0000000000 0000000
Vancouver, Canada
0
As of 0000
000.00
00000000000
000.00
000000 0
sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nos
0000000000000 00000000
Shanghai, China
00
As of 0000
00000000000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialIterative Scopes Competitors (11)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Boreal Genomics | Venture Capital-Backed | Vancouver, Canada | 0 | 000.00 | 00000000000 | 000.00 |
| 000000 00 | Venture Capital-Backed | Shanghai, China | 00 | 00000000000 | ||
| 000000 | Venture Capital-Backed | Irvine, CA | 00 | 00.000 | 00000000000 | 00.000 |
| 000000000 | Venture Capital-Backed | Hayward, CA | 000 | 000.00 | 000000 - 000 | 000.00 |
| 0000 000000 | Venture Capital-Backed | London, United Kingdom | 00 | 00000 | 0000000000 | 00000 |
Iterative Scopes Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Jonathan Ng | Founder, Chief Executive Officer & Board Member | ||
| Richard Kho Ph.D | Chief Operating Officer | ||
| Aditya Khosla Ph.D | Advisor |
Iterative Scopes Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Charlie Cooney | Wavemaker Partners | Board Member | 000 0000 |
| Jonathan Ng | Iterative Scopes | Founder, Chief Executive Officer & Board Member | 000 0000 |
| Lonne Jaffe | Iterative Scopes | Board Member | 000 0000 |
| Lotus Mallbris | Eli Lilly | Board Observer | 000 0000 |
| Marian Nakada Ph.D | Self | Board Observer | 000 0000 |
Iterative Scopes Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialIterative Scopes Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Alumni Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Clearlake Capital Group | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Insight Partners | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
| Breyer Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Eli Lilly | Corporation | Minority | 000 0000 | 000000 0 |